Maren Killackey

Bio:

Maren Killackey is VP, Head of Investor Relations & Communication at Generation Bio, a biotech company pioneering siRNA therapeutics to reshape what's possible for people with autoimmune diseases. With over a decade of experience in strategic communications, Maren specializes in crafting clear, compelling narratives that resonate with investors and stakeholders—helping raise over $1.5 billion to fuel innovation across the biotech space.
Before joining Generation Bio, she led investor relations and communications at Bicycle Therapeutics, where she built the function from the ground up and introduced the company’s Nobel Prize-inspired oncology platform to Wall Street. She got her start at Sage Therapeutics, where she helped secure funding for Zulresso—the first FDA-approved treatment for postpartum depression.
At Generation Bio, Maren recently led a company-wide communications pivot, aligning internal and external messaging to support a bold new strategy in a tough market. She continues to drive investor and corporate communications to support the company’s first-in-class T cell-targeted siRNA platform.
Maren holds a B.A. in Political Science from Columbia College at Columbia University. Outside of work, she’s a curious mind with a passion for AI ethics, women’s basketball, indie films, niche music, and solo travel adventures.